Craft

Fulgent Genetics

Stock Price

$20

2024-10-29

Market Capitalization

$606.8 M

2024-10-29

Revenue

$322.7 M

FY, 2025

Fulgent Genetics Summary

Company Summary

Overview
Fulgent Therapeutics is a technology company offering large-scale COVID-19 testing services, molecular diagnostic testing services, and comprehensive genetic testing. Its offerings consist of a wide variety of tests and test types that are designed to test particular genes and mutations within these genes that relate to a wide range of specified conditions and diseases.
Type
Public
Status
Active
Founded
2011
HQ
Temple City, CA, US | view all locations
Website
https://fulgentgenetics.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer

    • Brandon Perthuis

      Brandon Perthuis, Chief Commercial Officer

    • Lawrence Weiss, Chief Medical Officer

    • Paul Kim, Chief Financial Officer

      Operating MetricsView all

      Customers

      1.8K
      38.5%

      FY, 2021

      Laboratory Space, sq. ft.

      89K
      270.8%

      FY, 2021

      Office Space Leased, sq. ft.

      61.6K

      FY, 2021

      LocationsView all

      2 locations detected

      • Temple City, CA HQ

        United States

        4978 Santa Anita Ave

      • Houston, TX

        United States

        8554 Katy Fwy # 112

      Fulgent Genetics Financials

      Summary Financials

      Revenue (Q1, 2026)
      $71.1M
      Gross profit (Q1, 2026)
      $21.5M
      Net income (Q1, 2026)
      ($25.3M)
      Cash (Q1, 2026)
      $23.4M
      EBIT (Q1, 2026)
      ($34.6M)
      Enterprise value
      $583.9M

      Footer menu